Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
crispr
3
×
deals
3
×
life sciences
national blog main
san francisco blog main
abbvie
allergan
biotech
boston
boston top stories
clinical trials
editas medicine
gene editing
national top stories
san francisco top stories
startups
akouos
alnylam pharmaceuticals
alzheimer's disease
amag pharmaceuticals
amunix
anirvan ghosh
astrazeneca
biogen
bluerock therapeutics
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
cerovene
covid-19
cynthia collins
david walt
deerfield management
detroit blog main
detroit top stories
diagnostics
durvalumab
europe blog main
What
medicines
3
×
bio
editing
gene
years
abbvie
acquisitions
alliance
announced
biotech
ceo
collabs
covid
create
crispr
daniel
deal
diagnostic
diseases
editas
exits
experimental
fix
genetic
gilead
gilead’s
heats
help
high
human
introduce
ipo
launches
month
o’day
pact
partnership
plans
pruning
race
Language
unset
Current search:
deals
×
medicines
×
crispr
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M